These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 10810396)
21. Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma. Oda Y; Sakamoto A; Satio T; Kawauchi S; Iwamoto Y; Tsuneyoshi M Mod Pathol; 2000 Sep; 13(9):994-1004. PubMed ID: 11007040 [TBL] [Abstract][Full Text] [Related]
22. p53, p21, Rb and mdm2 oncoproteins. Expression in normal placenta, partial and complete mole, and choriocarcinoma. Fulop V; Mok SC; Genest DR; Gati I; Doszpod J; Berkowitz RS J Reprod Med; 1998 Feb; 43(2):119-27. PubMed ID: 9513873 [TBL] [Abstract][Full Text] [Related]
23. Immunohistochemical detection of bcl2, p53, mdm2 and p21/waf1 proteins in small-cell lung carcinomas. Stefanaki K; Rontogiannis D; Vamvouka C; Bolioti S; Chaniotis V; Sotsiou F; Vlychou M; Delidis G; Kakolyris S; Georgoulias V; Kanavaros P Anticancer Res; 1998; 18(2A):1167-73. PubMed ID: 9615783 [TBL] [Abstract][Full Text] [Related]
24. No evidence for functional inactivation of wild-type p53 protein by MDM2 overexpression in gastric carcinogenesis. Blok P; Craanen ME; Dekker W; Offerhaus GJ; Tytgat GN J Pathol; 1998 Sep; 186(1):36-40. PubMed ID: 9875138 [TBL] [Abstract][Full Text] [Related]
25. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas]. Shao HL; Shen DH; Xue WC; Li Y; Yu YZ Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760 [TBL] [Abstract][Full Text] [Related]
26. p53 and mdm2 as prognostic indicators in patients with epithelial ovarian cancer: a multivariate analysis. Dogan E; Saygili U; Tuna B; Gol M; Gürel D; Acar B; Koyuncuoğlu M Gynecol Oncol; 2005 Apr; 97(1):46-52. PubMed ID: 15790436 [TBL] [Abstract][Full Text] [Related]
27. [The expression of Mdm2 protein and p53 mutation in lung squamous cell carcinomas and their clinicopathological significance]. Zhang J; Liu H; Li S; Gu C Zhonghua Jie He He Hu Xi Za Zhi; 1999 Mar; 22(3):163-5. PubMed ID: 11812371 [TBL] [Abstract][Full Text] [Related]
28. Type IV collagen and CD44v6 expression in benign, malignant primary and metastatic ovarian tumors: correlation with Ki-67 and p53 immunoreactivity. Bar JK; Grelewski P; Popiela A; Noga L; Rabczyñski J Gynecol Oncol; 2004 Oct; 95(1):23-31. PubMed ID: 15385106 [TBL] [Abstract][Full Text] [Related]
29. Comparative immunohistochemical studies of bcl-2 and p53 proteins in benign and malignant ovarian endometriotic cysts. Nezhat F; Cohen C; Rahaman J; Gretz H; Cole P; Kalir T Cancer; 2002 Jun; 94(11):2935-40. PubMed ID: 12115382 [TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical detection of p53, mdm2, waf1/p21, and Ki67 proteins in bone marrow biopsies in myelodysplastic syndroms, acute myelogenous leukaemias and chronic myeloproliferative disorders. Kanavaros P; Stefanaki K; Rontogianni D; Darivianaki K; Vlychou M; Papadaki E; Eliopoulos G; Bakiri M; Matsouka C; Kakolyris S; Georgoulias V Clin Exp Pathol; 1999; 47(5):231-8. PubMed ID: 10598372 [TBL] [Abstract][Full Text] [Related]
31. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer. Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509 [TBL] [Abstract][Full Text] [Related]
32. Alterations affecting the p53 control pathway in bilharzial-related bladder cancer. Osman I; Scher HI; Zhang ZF; Pellicer I; Hamza R; Eissa S; Khaled H; Cordon-Cardo C Clin Cancer Res; 1997 Apr; 3(4):531-6. PubMed ID: 9815716 [TBL] [Abstract][Full Text] [Related]
33. p53/MDM-2 immunohistochemical expression correlated with proliferative activity in different subtypes of human sarcomas: a ten-year follow-up study. Stefanou DG; Nonni AV; Agnantis NJ; Athanassiadou SE; Briassoulis E; Pavlidis N Anticancer Res; 1998; 18(6B):4673-81. PubMed ID: 9891539 [TBL] [Abstract][Full Text] [Related]
34. [TP53 gene aberrations in chondromatous neoplasms: correlation with immunohistochemical p53 accumulation and MDM2 expression]. Blasenbreu S; Baretton GB; Bender C; Haas CJ; Diebold J; Löhrs U Verh Dtsch Ges Pathol; 1998; 82():284-9. PubMed ID: 10095448 [TBL] [Abstract][Full Text] [Related]
35. Expression of P53, MDM2 and Ki-67 antigens in soft tissue sarcomas. Szadowska A; Olborski B; Harezga-Bal B; Debiec-Rychter M Pol J Pathol; 1999; 50(1):9-16. PubMed ID: 10412269 [TBL] [Abstract][Full Text] [Related]
36. Nuclear accumulation of MDM2 protein in well-differentiated papillary thyroid carcinomas. Jennings T; Bratslavsky G; Gerasimov G; Troshina K; Bronstein M; Dedov I; Alexandrova G; Figge J Exp Mol Pathol; 1995 Jun; 62(3):199-206. PubMed ID: 8612724 [TBL] [Abstract][Full Text] [Related]
37. A molecular and immunohistochemical study of the MDM2 protein isoforms and p53 gene product in bronchogenic carcinoma. Gorgoulis VG; Zoumpourlis V; Rassidakis GZ; Karameris A; Rassidakis AN; Spandidos DA; Kittas C J Pathol; 1996 Oct; 180(2):129-37. PubMed ID: 8976869 [TBL] [Abstract][Full Text] [Related]
38. High prognostic significance of Mdm2/p53 co-overexpression in soft tissue sarcomas of the extremities. Würl P; Meye A; Schmidt H; Lautenschläger C; Kalthoff H; Rath FW; Taubert H Oncogene; 1998 Mar; 16(9):1183-5. PubMed ID: 9528860 [TBL] [Abstract][Full Text] [Related]
39. Mdm2 gene amplification in gastric cancer correlation with expression of Mdm2 protein and p53 alterations. Günther T; Schneider-Stock R; Häckel C; Kasper HU; Pross M; Hackelsberger A; Lippert H; Roessner A Mod Pathol; 2000 Jun; 13(6):621-6. PubMed ID: 10874665 [TBL] [Abstract][Full Text] [Related]
40. [Relationship of PTEN, Mdm2 and p53 expression in astrocytoma]. Zhong XY; Sun YH; Chen YX Zhonghua Zhong Liu Za Zhi; 2003 Sep; 25(5):478-81. PubMed ID: 14575575 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]